Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections

Trends in Pharmacological Sciences

Volumn 33, Issue 5, 2012, Pages 289-294

  Venkatraman, Srikanth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 DIMETHYLHEXAHYDRO 2H FURO[2,3 C]PYRROLE 4 CARBOXYLIC ACID; 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXYLIC ACID; BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VIRUS GENOME;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG DISCOVERY; HEPATITIS C; HUMANS; PROLINE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84860526352     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.03.012     Document Type: Review

References (39)

1. Q.L. Choo Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
2. G. Kuo An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis Science 244 1989 362 364 (Pubitemid 19117878)
3. R.S. Brown Jr. Scope of worldwide hepatitis C problem Liver Transpl. 9 2003 S10 S13
4. A.J. Freeman Estimating progression to cirrhosis in chronic hepatitis C infection Hepatology 2001 809 816 (Pubitemid 32928008)
5. A. Wasley Epidemiology of hepatitis C: geographic differences and temporal trends Semin. Liver Dis. 20 2000 1 16 (Pubitemid 30421405)
6. J.G. McHutchison Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 339 1998 1485 1492
7. G.L. Davis Interferon alfa-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C N. Engl. J. Med. 339 1998 1493 1499 (Pubitemid 28543497)
8. S. Zeuzem Peginterferon alfa-2a in patients with chronic hepatitis C N. Engl. J. Med. 343 2000 1666 1672
9. M.P. Manns Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965 (Pubitemid 32913521)
10. M.J. Evans Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801 806
11. A. Ploss Human occluding is a hepatitis C virus entry factor required for infection of mouse cells Nature 457 2009 882 886
12. P. Pileri Binding of hepatitis C virus to CD81 Science 282 1998 938 941 (Pubitemid 28507525)
13. E. Scarselli The human scavenger receptor class B type 1 is a novel candidate receptor for the hepatitis C virus EMBO J. 21 2002 5017 5025
14. B.D. Lindenbach Unravelling hepatitis C virus replication from genome to function Nature 436 2005 933 938 (Pubitemid 41191668)
15. K.E. Reed Molecular characterization of hepatitis C virus H.W. Reesink, Hepatitis C Virus 1998 Karger 1 37
16. R. Bartenschlager The NS3/4A proteinase of the hepatitis C virus: unraveling structure and function of an unusual enzyme and a prime target for antiviral therapy J. Virol. Hepat. 6 1999 165 181 (Pubitemid 29260100)
17. R. Bartenschlager Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions J. Virol. 67 1993 3835 3844 (Pubitemid 23180705)
18. Y. Yan Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 resolution structure in a hexagonal crystal form Protein Sci. 7 1998 837 847
19. R. Love The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site Cell 87 1996 331 342 (Pubitemid 26359010)
20. J.L. Kim Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding Structure 6 1998 89 100 (Pubitemid 28084402)
21. A.D. Kwong Hepatitis C virus NS3/4A protease Antivir. Res. 40 1998 1 18 (Pubitemid 28535168)
22. C. Steinkuhler Activity of purified hepatitis C virus protease NS3 on peptide substrates J. Virol. 70 1996 6694 6700 (Pubitemid 26307375)
23. A. Urbani Substrate specificity of the hepatitis C virus serine protease NS3 J. Biol. Chem. 272 1997 9204 9209 (Pubitemid 27154928)
24. A.A. Kolykhalov Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing J. Virol. 68 1994 7525 7533 (Pubitemid 24328808)
25. V. Lohmann Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113 (Pubitemid 29307577)
26. H. Akari Non-human primate surrogate model of hepatitis C virus infection Microbiol. Immunol. 53 2009 53 57
27. R.E. Lanford The chimpanzee model of hepatitis C infections and small animal surrogates S.-L. Tan, Y. He, Hepatitis C: Antiviral Drug Discovery and Development 2011 Caister Academic Press 103 135
28. E. Ohara Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice J. Hepatol. 54 2011 872 878
29. J.F. Morrison The behavior and significance of slow binding enzyme inhibitors Adv. Enzymol. 61 1988 201 301
30. 1 cyclopropyl alanine combination for improved potency Bioorg. Med. Chem. Lett. 15 2005 4515 4519
31. S.L. Bogen Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication J. Med. Chem. 49 2006 2750 2757
32. A. Mamai Poly-L-proline type-II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system J. Org. Chem. 66 2001 455 460 (Pubitemid 32105561)
33. S. Venkatraman Discovery of (1R,5 S)-N-[3-amino-1-(cyclobutylmethyl)-2-3- dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)-amino]carbonyl]amio]-3, 3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection J. Med. Chem. 49 2006 6074 6086 (Pubitemid 44484951)
34. K.-C. Cheng Use of pre-clinical in vitro and in vivo pharmacokinetics for selection of potent hepatitis C protease inhibitor, Boceprevir, for clinical development Lett. Drug Des. Discov. 6 2009 312 318
35. A.J. Prongay Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034). Key steps in structure-based optimization J. Med. Chem. 50 2007 2310 2318 (Pubitemid 46799243)
36. X. Tong Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antivir. Res. 70 2006 28 38
37. P.Y. Kwo Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
38. F. Poordad Boceprevir for untreated chronic HCV genotype 1 infection N. Engl J. Med. 364 2011 1195 1206
39. B.R. Bacon Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1207 1217